Celecoxib (100 and 200 mg cap): Supply issue resolved

The funded brand of celecoxib has changed due to supply issues with the previous brand.

27 July 2023

Celebrex is the available brand. Stock of Celecoxib Pfizer has run out. Pharmac will move to delist Celecoxib Pfizer later in 2023 to allow time for all stock to be claimed. 

Affected products

The supplier notified us of ongoing supply challenges impacting the Celecoxib Pfizer capsules.

  • Chemical: Celecoxib
  • Presentations: Cap 100 mg / Cap 200 mg 
  • Brand: Celecoxib Pfizer
  • Pharmacode: 2521164 / 2521172
  • Subsidy: $3.45 / $3.20
  • Measure / Qty: per 60 / per 30

Schedule listing for celecoxib(external link)

Replacement product listed

We brought forward the listing of Celebrex to 1 August 2022 (100 mg Pharmacode 2642433 | 200 mg Pharmacode 2642441).

Schedule listings for Celebrex(external link)

Celebrex is now the available brand from the supplier. 

What stayed the same

Celebrex capsules look identical to and are the same as Celecoxib Pfizer capsules. The capsules have the same active ingredient and work in the body in the same way. They are both supplied by Aspen Pharmacare. 

The Celebrex brand products are approved by Medsafe. 

Who to contact

If you have any questions about the new look packaging, talk with your doctor, nurse or pharmacist.

Pharmacies can contact their wholesalers for enquiries about stock availability.

If you have any other questions about this issue, email enquiry@pharmac.govt.nz

Pharmacists, please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.